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& Abstract
Objective: To evaluate the effectiveness of tapentadol
prolonged release (PR) vs. oxycodone/naloxone PR in non–
opioid-pretreated patients with severe chronic low back pain
with a neuropathic pain component.
Methods: Eligible patients (average pain intensity [numer-
ical rating scale-3 (NRS-3)] ≥6; painDETECT positive/unclear)
were randomized to twice-daily tapentadol PR 50 mg or
oxycodone/naloxone PR 10 mg/5 mg. After a 21-day titration
(maximum twice-daily doses: tapentadol PR 250 mg, or
oxycodone/naloxone PR 40 mg/20 mg plus oxycodone PR
10 mg), target doses were continued for 9 weeks. The
primary effectiveness endpoint was the change in NRS-3
from baseline to final evaluation; the exact repeated confi-
dence interval (RCI) for tapentadol PR minus oxycodone/
naloxone PR was used to establish noninferiority (upper limit
<1.3) and superiority (confirmatory analyses).
Results: For the primary effectiveness endpoint, tapentadol
PR was noninferior to oxycodone/naloxone PR (97.5% RCI:
[1.820, 0.184]; P < 0.001). This exact RCI also yielded
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evidence of superiority for tapentadol PR vs. oxycodone/
naloxone PR (significantly greater reduction in pain intensity;
P = 0.003). Improvements (baseline to final evaluation) in
painDETECT and Neuropathic Pain Symptom Inventory scores
were significantly greater with tapentadol PR vs. oxycodone/
naloxone PR (all P ≤ 0.005).
Conclusions: The study was formally shown to be positive
and demonstrated, in the primary effectiveness endpoint, the
noninferiority for tapentadol PR vs. oxycodone/naloxone PR.
The effectiveness of tapentadol PR was superior to that of
oxycodone/naloxone PR by means of clinical relevance and
statistical significance (confirmatory evidence of superiority).
Tapentadol PR was associated with significantly greater
improvements in neuropathic pain-related symptoms and
global health status than oxycodone/naloxone PR and with a
significantly better gastrointestinal tolerability profile. Ta-
pentadol PR may be considered a first-line option for
managing severe chronic low back pain with a neuropathic
pain component. &
Key Words: effectiveness, tapentadol prolonged release,
chronic low back pain, neuropathic pain, randomized con-
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INTRODUCTION
Low back pain is one of the most common chronic pain
conditions worldwide1 and is frequently associated with
a neuropathic pain component.2,3 Up to 79% of patients
with severe and disabling low back pain have at least a
possible neuropathic component to their low back
pain.3 Chronic pain with a neuropathic component is
often difficult to diagnose and manage4,5 and may be
more severe than chronic pain without a neuropathic
component.6 Although opioids are frequently used for
chronic pain management, they are often associated
with poor tolerability that may lead to treatment
discontinuation.7–9 Gastrointestinal side effects, such
as constipation, may be particularly problematic for
patients receiving long-term opioid therapy; opioid-
induced constipation typically does not improve with
continued treatment and may be refractory to standard
treatments.8,10 Opioid-induced bowel dysfunction is
mediated by opioid binding to receptors in the gastro-
intestinal tract; this results in a disruption of
gastrointestinal motility and mucosal secretions, and
accompanying symptoms, such as constipation.9
One strategy that has been developed to address
opioid-induced bowel dysfunction is the coadministra-
tion of opioid analgesics with an opioid antagonist, such
as naloxone, which is proposed to act on the opioid
receptors of the gastrointestinal tract, blocking the
unwanted side effects.11,12 A fixed-dose combination
of oxycodone/naloxone prolonged release (PR) has been
shown to be effective and well tolerated for the
management of moderate to severe chronic low back
pain,11 with better gastrointestinal tolerability (less
constipation) compared with oxycodone PR alone.11,12
Tapentadol is a centrally acting analgesic with 2
mechanisms of action, l-opioid receptor (MOR) agon-
ism and noradrenaline reuptake inhibition (NRI).13,14
Results from preclinical studies have demonstrated
synergism between both mechanisms of action with
respect to efficacy,15,16 while lack of synergy has been
demonstrated for gastrointestinal side effects.17 The
NRI activity of tapentadol contributes to its action on
neuropathic pain and may provide an opioid-sparing
effect, maintaining analgesic efficacy while reducing the
potential for side effects associated with l-opioid
agonism.14 Tapentadol has also been shown to re-
establish descending pain inhibition in patients with
pain related to diabetic peripheral neuropathy, which
may counteract pain chronification.18 The effectiveness
of tapentadol PR has been demonstrated for the man-
agement of severe chronic low back pain with a
neuropathic pain component in recent phase 3b stud-
ies.19,20 Tapentadol PR has also been shown to be
effective for managing moderate to severe chronic
osteoarthritis knee pain,21,22 low back pain,22,23 pain
related to diabetic peripheral neuropathy,24 and cancer
pain.25–27 In a pooled analysis of data from 3 random-
ized, double-blind, placebo- and active-controlled,
phase 3 studies in patients with moderate to severe
chronic osteoarthritis pain or low back pain, tapentadol
PR (100 to 250 mg bid) provided noninferior and even
superior analgesic efficacy to that of oxycodone PR (20
to 50 mg bid), with superior gastrointestinal tolerabil-
ity, based on assessments of the incidences of nausea,
vomiting, and constipation.28
A recent randomized, multicenter, parallel-arm,
open-label, active-controlled, phase 3b/4 effectiveness
study (ClinicalTrials.gov Identifier: NCT01838616)
was designed to evaluate the effectiveness and tolera-
bility of tapentadol PR compared with that of oxyco-
done/naloxone PR for the management of severe chronic
low back pain with a neuropathic pain component in
non–opioid-pretreated patients. That study had 2
primary endpoints: a primary effectiveness endpoint
and a co-primary endpoint that evaluated changes in
bowel function (based on the Patient Assessment of
Constipation Symptoms [PAC-SYM] total score) with
study treatment. Detailed results for the co-primary
endpoint, along with tolerability, safety, and quality of
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life outcomes, will be presented separately.29 Results for
the primary effectiveness endpoint, measures of
neuropathic pain-related symptoms, and global mea-
sures of health status are presented here.
METHODS
The protocol, patient information sheet, and informed
consent form for this study were reviewed and approved
by independent ethics committees. This study was
conducted according to good clinical practice guide-
lines, applicable local laws, and the ethical principles
laid out in the Declaration of Helsinki.
Patients
This study included men and women who were
≥18 years of age with severe chronic low back pain
with a neuropathic pain component. Chronic low back
pain was identified in patients with diagnosed low back
pain lasting ≥3 months prior to enrollment. Eligible
patients had pain requiring a strong (World Health
Organization [WHO] step III) analgesic, based on the
investigator’s assessment. At enrollment, patients who
were not taking co-analgesics were required to have an
average pain intensity score of ≥6 on an 11-point
numerical rating scale-3 (NRS-3; recalled average pain
intensity score [11-point NRS] during the last 3 days
prior to the visit; 0 = “no pain” to 10 = “pain as bad as
you can imagine”). Patients whowere taking co-analgesics
at enrollment, which must have been discontinued
during the washout period prior to randomization, were
required to have an average pain intensity score of ≥5 on
an 11-point NRS-3. At randomization, all patients were
required to have an average pain intensity score of ≥6.
The neuropathic component of patients’ low back pain
was evaluated using the painDETECT questionnaire
(possible score of 0 to 38; increasing scores indicate the
increasing probability of the presence of a neuropathic
pain component).2 At enrollment, patients were required
to have a score on the painDETECT questionnaire of
≥13, with scores of 13 to 18 classified as unclear and
scores of 19 to 38 classified as positive. For patients
taking a stable regimen of centrally acting co-analgesics,
which must have been discontinued during the washout
period prior to randomization, a score of ≥9 (classified as
negative) was permitted at enrollment. At randomization
(after washout), all patients were required to have a
painDETECT score in line with a classification of
positive or unclear.
Patients were not eligible for the study if their low
back pain was caused by cancer and/or metastatic
diseases. Patients were also not eligible for the study if
they had any clinically significant disease, active sys-
temic or local infections, or clinically significant labo-
ratory values, or required any painful procedures
(scheduled during the study) that could (in the investi-
gator’s opinion) affect effectiveness, quality of life, or
safety and tolerability assessments. Patients were
excluded from the study if they had a history of alcohol
or drug abuse; acute intoxication with alcohol, hypnot-
ics, centrally acting analgesics, or psychotropic active
substances; or a history of allergy or hypersensitivity to
tapentadol, oxycodone, naloxone, or their formulations.
Patients were also excluded from the study if they had a
history of seizure disorder or epilepsy; mild or moderate
traumatic brain injury, stroke, transient ischemic attack,
or brain neoplasm within 1 year; severe traumatic brain
injury within 15 years or residual sequelae suggesting
transient changes in consciousness; or severe cardiac
impairment (eg, New York Heart Association class >3,
myocardial infarction <6 months prior to enrollment,
unstable angina pectoris, cor pulmonale). Additional
exclusion criteria included the presence of concomitant
autoimmune inflammatory conditions; hypothyroidism
(including myxedema) or Addison’s disease; severe renal
impairment or a history of or current laboratory values
reflecting moderately or severely impaired hepatic func-
tion; severe respiratory depression with hypoxia and/or
hypercapnia, acute or severe bronchial asthma, or severe
chronic obstructive pulmonary disease; known or sus-
pected paralytic ileus, acute biliary obstruction, or acute
pancreatitis; or a history of rare hereditary problems of
galactose intolerance, Lapp lactase deficiency, or glu-
cose–galactose malabsorption.
Concomitant Medications
During the study, patients who were on a stable
prestudy regimen of nonsteroidal anti-inflammatory
drugs (NSAIDs) or paracetamol were permitted to
continue taking those medications at the same stable
dose. Selective serotonin reuptake inhibitors were per-
mitted for the treatment of uncomplicated depression if
patients had been taking a stable dose for ≥30 days prior
to randomization. Medications used to treat psychiatric
or neurologic disorders (other than those described in
the following paragraph as prohibited) were permitted if
patients had been taking a stable dose for ≥3 months
prior to randomization.
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With the exception of NSAIDs and paracetamol (as
previously described), all analgesics and co-analgesics
were prohibited during the study after the washout
period. WHO step II and III analgesics, except for study
drug, were prohibited within 30 days prior to random-
ization and during the study. Laxatives and anti-emetics
as prophylaxis were prohibited within 14 days prior
to randomization and during the study. Monoamine
oxidase inhibitors were prohibited within 14 days prior
to randomization and during the study.
Study Design
This study included a 3- to 14-day washout period, a
3-week titration period, and a 9-week continuation
period (Figure 1). Patients who were taking centrally
acting analgesics or co-analgesics at enrollment were
required to discontinue these analgesics or co-analge-
sics during the washout period prior to the random-
ization visit and the start of study treatment; the
duration of the washout period was individualized
depending on the type and dose of the previous co-
analgesics. At the randomization visit, patients were
randomized 1:1 to initial doses of tapentadol PR
50 mg bid or oxycodone/naloxone PR 10 mg/5 mg
bid. During the titration period, doses could be
titrated upwards in increments of tapentadol PR
50 mg bid until the minimum target of titration was
reached; the maximum permitted doses were tapent-
adol PR 250 mg bid and oxycodone/naloxone PR
40 mg/20 mg bid plus oxycodone PR 10 mg bid. The
minimum target of titration at the end of the titration
period was defined as one of the following: (1) a pain
intensity score (NRS-3) of ≤4 with acceptable tolera-
bility as reported by the patient or (2) a pain intensity
score of ≤5 if pain relief and tolerability were reported
by the patient and investigator as satisfactory to
continue in the study and the patient was on the
maximum dose of tapentadol PR or oxycodone/
naloxone PR (or the maximum daily dose could not
be achieved because of side effects). Patients who
reached the minimum target of titration were eligible
to enter a 9-week continuation period, during which
they continued on the same stable dose of study drug;
a single titration step (up- or down-titration; for
patients taking the maximum dose, only down-titra-
tion) using the same increments as during titration was
permitted during the continuation period. Patients in
the tapentadol PR group who did not reach the
minimum target of titration by the end of the titration
period were discontinued from the study. Patients in
the oxycodone/naloxone PR group who did not reach
the minimum target of titration by the end of the
titration period because of intolerable side effects or a
lack of efficacy could be switched to tapentadol PR in
a pickup arm or discontinued from the study. The
option to switch to the pickup arm because of a lack
of tolerability or efficacy under treatment with oxyco-
done/naloxone PR was possible at any time during the
titration and continuation periods.
Study Evaluations
Effectiveness. Patients rated their average pain intensity
during the past 3 days on an 11-point NRS at each study
visit or telephone call. The primary effectiveness end-
point (1 of 2 co-primary endpoints for this study) was
the change in average pain intensity during the last
3 days (NRS-3) from the randomization visit (baseline)
to final evaluation at the end of the continuation period
or at the time of discontinuation. The second primary
endpoint of the study was the change in the PAC-SYM
total score from the randomization visit (baseline) to
final evaluation at the end of the continuation period or
at the time of discontinuation; results for that endpoint
will be presented separately.
Pain intensity scores over time and changes from
baseline in pain intensity scores over time were evalu-
ated as secondary effectiveness endpoints. Pain intensity
scores (11-point NRS-3) for pain radiating toward or
into the leg were also evaluated as a secondary endpoint.
The patient global impression of change (PGIC) and
clinician global impression of change (CGIC), which
were used to evaluate patients’ global health status, were
also evaluated as secondary effectiveness endpoints. The
PGIC and CGIC were completed at the randomization
visit, weekly during titration (Visits 4, 6, and 8), twice
during the continuation period (Visits 9 and 10), and at
the final evaluation visit. For the PGIC, which is a
recommended and responsive outcome for clinical trials
in pain,30,31 patients rated their overall impression of
their status using a 7-point scale (1 = “very much
improved” to 7 = “very much worse”). For the CGIC,32
investigators rated their impression of the change in
patients’ condition with treatment using the same 7-
point scale as the PGIC.
Neuropathic Pain Outcomes. Changes in neuropathic
pain symptoms, based on the painDETECT questionnaire
and the Neuropathic Pain Symptom Inventory (NPSI),
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were evaluated as secondary endpoints. The painDE-
TECT questionnaire2 was completed at the enrollment
visit, at the randomization visit, at the end of titration
(Visit 8), and at the final evaluation visit; the NPSI33 was
completed at the enrollment visit, at the randomization
visit, weekly during titration (Visits 4, 6, and 8), twice
during the continuation period (Visits 9 and 10), and at
the final evaluation visit. The painDETECT question-
naire, which has been validated for showing the effect of
treatment on neuropathic pain symptoms over time,34
includes 7 questions addressing the frequency and
quality of neuropathic pain symptoms (scored from 0
to 5; 0 = “never” to 5 = “very strongly”), 1 question
addressing pain patterns over time, and 1 question
evaluating radiating pain. The NPSI33 is a validated
measure that includes 10 items used to evaluate the
properties of neuropathic pain; each item is scored on an
11-point NRS, with higher scores indicating more severe
neuropathic pain symptoms. The NPSI33 also includes a
measure of the number of pain attacks during the
previous 24 hours.
Prior to randomization to study treatment, lumbar
radiculopathy was diagnosed in patients with dermato-
mal pain that radiated beyond the knee toward the foot
and was evoked by stretching of the sciatic nerve. For a
diagnosis of lumbar radiculopathy, patients were also
required to have ≥1 of the following signs of root
dysfunction: (1) sensory impairment, motor symptoms
from compression of the lumbar nerve root; (2) absent
or diminished reflexes related to affected dermatomes;
and/or (3) sensory deficits in the affected painful
dermatomal area, demonstrated by quantitative sensory
testing.
Tolerability Outcomes and Dosing. Treatment-emer-
gent adverse events (TEAEs) and discontinuations were
monitored and recorded throughout the study. The
mean daily doses of tapentadol PR and oxycodone/
naloxone PR were evaluated during the titration and
continuation periods.
Statistical Analyses
This study had an adaptive, 3-stage, group-sequential
design (O’Brien and Fleming type design35); the results
presented here are those of the final analysis. A 2-sample
t-test was used for the calculation of the sample size. For
both primary endpoints, a sample size of 96 patients per
group in the per protocol set was required to show the
noninferiority of tapentadol PR, as compared with
oxycodone/naloxone PR, with 90% power and a 1-sided
significance level of a = 0.0125. Assuming that 80% of
patients were available for the per protocol set, a total of
240 patients had to be allocated to study treatment.
Statistical methods for the second primary endpoint (the
change in the PAC-SYM total score) will be presented
separately.
The safety set, which was used for the analysis of all
patient characteristics and tolerability outcomes,
included all randomized patients who took ≥1 dose of
study drug. The full analysis set, which was used for the
analysis of all secondary efficacy and quality of life
endpoints, included all randomized patients who took
≥1 dose of study drug and had ≥1 postbaseline pain
intensity assessment (NRS-3). The per protocol set,
which was used for the analysis of the primary
effectiveness endpoint, was a subpopulation of the full
analysis set that included all patients who had no major
protocol deviations that could impact the primary
outcomes of the study.
For the primary effectiveness endpoint (the change
from baseline to final evaluation in average pain
intensity [NRS-3]), tapentadol PR was considered to
be noninferior to oxycodone/naloxone PR if the upper
limit of the 2-sided 97.5% exact repeated confidence
interval (RCI) for the treatment difference (tapentadol PR
Figure 1. Studydesign.NRS-3, numerical
rating scale-3; PR, prolonged release;
W, week; V, visit; bid, twice daily.
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minus oxycodone/naloxone PR) was less than the
noninferiority margin of 1.3. This RCI was also the
basis for switching from noninferiority to superiority.36
If the upper limit of the exact RCI was below 0,
tapentadol PR also demonstrated evidence of superiority
compared with oxycodone/naloxone PR in terms of
statistical significance at the 1.25% level.
The main analysis for the primary efficacy endpoint
(RCI) was adjusted for the group-sequential design and
multiplicity, guaranteeing overall control of type I error
rate (2.5% 1-sided). Confirmatory P values for nonin-
feriority and superiority, based on the inverse normal
method, have been determined, thus adjusting for the
group-sequential design. Because there were 2 co-
primary endpoints, these P values must be compared
to the 1-sided significance level of 1.25%. Further
analyses of the primary endpoints were exploratory and
were not adjusted for multiplicity. As a sensitivity
analysis to demonstrate the robustness of the results of
the primary endpoints, the primary analyses were
repeated using the full analysis set.
All other outcomes presented here are for secondary
endpoints, and the respective analyses were exploratory
and not adjusted for multiplicity. For the painDETECT
questionnaire, scores for the 9 individual questions were
summed to yield a total painDETECT score (possible
score, 0 to 38). For the NPSI, scores for the 10 individual
items evaluating the properties of neuropathic pain were
averaged and divided by 10 to yield 5 subscores (each
with a possible score of 0 to 1): burning pain (1 item),
pressing pain (2 items), paroxysmal pain (2 items),
evoked pain (3 items), and paresthesia/dysesthesia
(2 items). The scores for all 10 individual items were
also summed and divided by 100 to yield an overall
feeling score (possible score, 0 to 1).
Between-group differences in PGIC and CGIC
scores were evaluated using Fisher’s exact test. An
analysis of covariance (ANCOVA) model, including
treatment and pooled center as factors and baseline
value as a covariate, was used to evaluate painDETECT
and NPSI outcomes and to obtain necessary P values
for the primary effectiveness endpoint that was
required as input for the inverse normal method.
The last observation carried forward (LOCF) was
used for imputing missing scores. The patients who
entered the pickup arm were treated as discontinua-
tions using the LOCF.
Pain intensity and neuropathic pain outcome results
were evaluated separately for the subset of patients who
switched from oxycodone/naloxone PR to tapentadol
PR in the pickup arm and for the subsets of patients
divided by painDETECT rating at baseline (positive or
unclear). Pain intensity was also evaluated separately for




The safety set for this study included 258 patients
(tapentadol PR, n = 130; oxycodone/naloxone PR,
n = 128), the full analysis set included 256 patients
(tapentadol PR, n = 130; oxycodone/naloxone PR,
n = 126), and the per protocol set included 229 patients
(tapentadol PR, n = 117; oxycodone/naloxone PR,
n = 112). A total of 66.2% (86/130) of patients in the
tapentadol PR group and 37.5% (48/128) of patients in
the oxycodone/naloxone PR group completed study
treatment. In the tapentadol PR and oxycodone/nalox-
one PR groups, respectively, 23.1% (30/130) and 51.6%
(66/128) of patients discontinued treatment during
the titration period and 33.8% (44/130) and 62.5%
(80/128) of patients discontinued treatment during the
overall treatment period. The most common reasons for
study discontinuation during the overall treatment
period were adverse events (AEs) and lack of efficacy
(Figure 2). For the oxycodone/naloxone PR group, these
percentages of discontinuations included patients who
switched to tapentadol PR treatment in the pickup arm
(titration period, n = 43; continuation period, n = 7)
due to a lack of efficacy (titration period, n = 11;
continuation period, n = 4) or the occurrence of TEAEs
(titration period, n = 32; continuation period, n = 3).
Of the 50 patients who entered the pickup arm, 70.0%
(35/50) completed treatment; the reasons for discontin-
uation included AEs (18.0% [9/50]), a lack of efficacy
(8.0% [4/50]), withdrawal by the patient (4.0% [1/50]),
and technical problems (2.0% [1/50]).
Baseline and demographic characteristics were com-
parable between treatment groups in the safety set
(Table 1). The mean age was approximately 58 years in
both treatment groups, and there was a higher percent-
age of female than male patients in each treatment
group. The majority of patients (>70%) in both treat-
ment groups had a painDETECT positive rating at
baseline. A diagnosis of lumbar radiculopathy was made
at baseline for 58.5% (76/130) of patients in the
tapentadol PR group and 58.6% (75/128) of patients
in the oxycodone/naloxone PR group (Figure 3).
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The history of patients’ low back pain was
generally similar in both treatment groups. On
average, patients in both treatment groups had been
experiencing their chronic low back pain for approx-
imately 8 to 9 years (mean [standard deviation (SD)]
duration of pain: tapentadol PR, 115.8 [121.26]
months; oxycodone/naloxone PR, 102.4 [101.44]
months). In the tapentadol PR and oxycodone/nalox-
one PR groups, respectively, the mean (SD) number
of doctors that patients had visited since their pain
first started was 3.5 (2.22) and 3.3 (2.14), and
patients required a mean (SD) of 2.4 (2.33) and 2.5
(2.38) consultations about their pain during the
previous 3 months. A total of 26.9% (35/130) of
patients in the tapentadol PR group and 22.7%
(29/128) of patients in the oxycodone/naloxone PR
group had been hospitalized for their pain; on
average, patients in both treatment groups had been
hospitalized twice for their pain (mean [SD] number
of hospitalizations: 2.0 [1.09] and 2.2 [2.18], respec-
tively). The mean (SD) number of analgesic regimens
that patients had taken since their pain started was
3.3 (2.50) in the tapentadol PR group and 3.3 (2.25)
in the oxycodone/naloxone PR group.
During the titration period, mean (SD) daily doses
were 259.0 (80.05) mg/day in the tapentadol PR group
and 45.0 (18.33) mg/day in the oxycodone/naloxone PR
group; during the continuation period, mean (SD) daily
doses were 378.8 (129.61) and 75.3 (24.28) mg/day,
respectively. The mean (SD) daily dose in the pickup arm
was 301.9 (114.65) mg/day of tapentadol PR. The mean
(SD) duration of exposure was 62.9 (30.84) days in the
tapentadol PR group and 42.0 (34.22) days in the
oxycodone/naloxone PR group. The mean (SD) dura-
tion of exposure to tapentadol PR in the pickup arm was
52.3 (24.72) days.
Effectiveness
For the primary effectiveness endpoint, tapentadol PR
was noninferior to oxycodone/naloxone PR based on
the exact RCI of tapentadol PR minus oxycodone/
naloxone PR ([1.820, 0.184]; P < 0.001 for nonin-
feriority [inverse normal method]; confirmatory analy-
sis). Furthermore, this exact RCI did not include 0 and
therefore demonstrated evidence of the superiority of
tapentadol PR vs. oxycodone/naloxone PR in terms of
Figure 2. Patient disposition. PR,
prolonged release. aIncludes 50
patients who entered the open-label
pickup arm due to a lack of efficacy
(n = 15) or tolerability (n = 35).








Mean (SD) age, years 58.4 (12.23) 58.1 (11.48)
Gender, n (%)
Female 84 (65.6) 77 (59.2)
Male 44 (34.4) 53 (40.8)
Mean (SD) BMI, kg/m2 29.0 (5.69) 29.8 (5.55)
Race, n (%)
White 128 (100) 130 (100)
Baseline painDETECT score*
Positive 97 (75.8) 96 (73.8)
Unclear 27 (21.1) 33 (25.4)
PR, prolonged release; SD, standard deviation; BMI, body mass index.
*painDETECT ratings were not available for 1 patient in the tapentadol PR group and
4 patients in the oxycodone/naloxone PR group.
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statistical significance at the 1.25% level (confirmatory
analysis). The reduction in pain intensity was signifi-
cantly greater with tapentadol PR than with oxycodone/
naloxone PR (P = 0.003 for superiority; confirmatory
analysis). Results of the primary endpoint were sup-
ported by a sensitivity analysis in the full analysis set
using the LOCF (Table S1).
Mean pain intensity scores at baseline and final
evaluation are shown in Figure 4A. Significant reduc-
tions in pain intensity from baseline to final evaluation
(LOCF) were observed for both tapentadol PR and
oxycodone/naloxone PR in the per protocol set (both
P < 0.001 for the change from baseline; Figure 4B).
Mean pain intensity scores over time are shown in
Figure 5.
The pain intensity score for pain radiating toward or
into the leg improved significantly from baseline to final
evaluation in both treatment groups (P < 0.001; Fig-
ure 6). Improvements in pain intensity for pain radiating
toward or into the leg were significantly higher in the
tapentadol PR group than in the oxycodone/naloxone
PR group (P = 0.001; Figure 6).
On the PGIC, the percentage of patients who
reported a rating of “much improved” or “very much
improved” was significantly higher in the tapentadol PR
group (54.3% [70/129]) than in the oxycodone/nalox-
one PR group (29.6% [37/125]) at final evaluation
(P < 0.001; LOCF; Figure 7A). Overall, based on PGIC
results, most patients (78.5% [102/130]) in the tapent-
adol PR group rated their overall condition as improved.
Moreover, patients in the tapentadol PR group rated
their condition more favorably at final evaluation than
did patients in the oxycodone/naloxone PR group
(P = 0.005). On the CGIC, the percentage of patients
for whom investigators reported a rating of “much
improved” or “very much improved” was significantly
higher with tapentadol PR (59.4% [76/128]) than with
oxycodone/naloxone PR (35.0% [43/123]) at final
evaluation (P < 0.001; LOCF; Figure 7B). Overall,
based on CGIC results, investigators rated patients’
conditions more favorably at final evaluation with
tapentadol PR than with oxycodone/naloxone PR
(P = 0.005).
Neuropathic Pain-related Symptoms
The total painDETECT score decreased significantly
from baseline to final evaluation (LOCF) in both
treatment groups in the full analysis set (both
P < 0.001 for the change from baseline; Figure 8A,B).
The decrease in the total painDETECT score from
baseline to final evaluation was significantly greater in
the tapentadol PR group than in the oxycodone/nalox-
one PR group (least squares [LS] mean difference [95%
confidence interval (CI)],2.9 [4.7,1.0]; P = 0.002).
For all individual item scores describing symptoms of
neuropathic pain on the painDETECT questionnaire,
significant decreases from baseline to final evaluation
(LOCF) were observed in both treatment groups of the
full analysis set (all P < 0.001 for the change from
Figure 3. Diagnosis of lumbar
radiculopathy (full analysis set). PR,
prolonged release.
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baseline; Figure 8C). Significantly greater decreases
from baseline to final evaluation were observed in the
tapentadol PR group than in the oxycodone/naloxone
PR group for the following individual item scores:
suffering from a burning sensation in the marked area, a
tingling or prickling sensation in the area of pain, light
touching painful in the area (allodynia), cold or heat
occasionally painful in the area (thermal pain), and
slight pressure triggers pain in the area (evoked/pressure-
related pain; all P ≤ 0.029).
The NPSI overall feeling score decreased significantly
from baseline to final evaluation in the tapentadol PR
group (LS mean [standard error of the mean (SEM)]
change from baseline to final evaluation, 0.35 [0.021];
P < 0.001) and in the oxycodone/naloxone PR group
(0.25 [0.021]; P < 0.001) of the full analysis set. The
change from baseline in the overall feeling score was
significantly greater in the tapentadol PR group than in
the oxycodone/naloxone PR group (P < 0.001). Signif-
icant decreases were also observed in all NPSI subscores
from baseline to final evaluation in both treatment
groups of the full analysis set (all P < 0.001 for the
change from baseline). The improvements from baseline
tofinal evaluation in allNPSI subscoreswere significantly
greater in the tapentadol PR group than in the oxyco-
done/naloxone PR group (all P ≤ 0.005; Figure S1A).
Improvements from baseline in all NPSI subscores were
also significantly greater in the tapentadol PR group than
in the oxycodone/naloxone PR group fromVisit 8 (Week
3) until the end of the study (all P ≤ 0.012; Figure 9A).
The number of pain attacks during the previous
24 hours, as reported on the NPSI, decreased over
the course of the study in both treatment groups
A B
Figure 4. (A) Mean pain intensity at baseline and final evaluation and (B) change in pain intensity from baseline to final evaluation (LS
meana; LOCF; per protocol set). LS, least squares; LOCF, last observation carried forward; PR, prolonged release; SD, standard deviation;
NRS-3, numerical rating scale-3; BL, baseline; FE, final evaluation; SEM, standard error of the mean; ANCOVA, analysis of covariance.
*P < 0.001 for the change from baseline (exploratory analysis). †P < 0.001 (confirmatory analysis; noninferiority; tapentadol PR vs.
oxycodone/naloxone PR); P = 0.003 (confirmatory analysis; superiority; tapentadol PR vs. oxycodone/naloxone PR). aLS means were
obtained from an ANCOVA model that included treatment and pooled centers as factors and score at randomization (baseline) as a
covariate. bPercent difference from baseline, 38.6%. cPercent difference from baseline, 48.7%. dPercent difference between
tapentadol PR and oxycodone/naloxone PR, using oxycodone/naloxone PR as the base (denominator), 37.0%.
Figure 5. Changes from baseline in pain intensity scores over
time (LS mean; LOCF; full analysis set).a,b,c LS, least squares; LOCF,
last observation carried forward; PR, prolonged release; NRS-3,
numerical rating scale-3; BL, baseline; V, visit; W, week; FE, final
evaluation; SEM, standard error of the mean; ANCOVA, analysis
of covariance. *P < 0.001 for the change from baseline.
†P = 0.012 (superiority; tapentadol PR vs. oxycodone/naloxone
PR). ‡P ≤ 0.002 (superiority; tapentadol PR vs. oxycodone/nalox-
one PR). aExploratory analyses. bLS means were obtained from an
ANCOVA model that included treatment and pooled centers as
factors and score at randomization (baseline) as a covariate.
cSEM: oxycodone/naloxone PR, BL = 0, V3 = 0.13, V4 = 0.15,
V5 = 0.18, V6 = 0.18, V7 = 0.19, V8 = 0.20, V9 = 0.23,
V10 = 0.24, FE = 0.24; tapentadol PR, BL = 0, V3 = 0.12,
V4 = 0.15, V5 = 0.17, V6 = 0.18, V7 = 0.19, V8 = 0.20, V9 = 0.22,
V10 = 0.23, FE = 0.24.
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A B
Figure 6. (A) Mean pain intensity at baseline and final evaluation and (B) change in pain intensity from baseline to final evaluation for
pain radiating toward or into the leg (LS mean; LOCF; full analysis set).a,b LS, least squares; LOCF, last observation carried forward; SD,
standard deviation; BL, baseline; FE, final evaluation; SEM, standard error of themean; PR, prolonged release. *P < 0.001 for the change
from baseline. †P < 0.001 (noninferiority; tapentadol PR vs. oxycodone/naloxone PR); P = 0.001 (superiority; tapentadol PR vs.
oxycodone/naloxone PR). aExploratory analyses. bLS meanswere obtained from an ANCOVAmodel that included treatment and pooled
centers as factors and score at randomization (baseline) as a covariate.
A
B
Figure 7. (A) PGIC ratings at final evaluation and (B) CGIC ratings at final evaluation (LOCF; full analysis set).a,b,c PGIC, patient global
impression of change; CGIC, clinician global impression of change; LOCF, last observation carried forward; PR, prolonged release.
*P = 0.005 (overall distribution of responses; superiority; tapentadol PR vs. oxycodone/naloxone PR). †P < 0.001 (superiority; tapentadol
PR vs. oxycodone/naloxone PR). aExploratory analyses. bn values are the numbers of patients with PGIC or CGIC results available for final
evaluation. cSummary percentages for the “much improved” and “very much improved” categories may differ from the sum of those 2
percentages due to rounding.
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(Figure S1B). Patients generally reported fewer pain
attacks in the tapentadol PR group than in the oxyco-
done/naloxone PR group at final evaluation (P = 0.008;
Fisher’s exact test; Figure 9B). A clear reduction in pain
attacks was observed from baseline to final evaluation in
both groups, but to a higher extent in the tapentadol PR
group. A higher percentage of patients experienced no
pain attacks during the previous 24 hours at final
evaluation with tapentadol PR (31.0% [40/129])
than with oxycodone/naloxone PR (14.4% [18/125]),
indicating that patients in the tapentadol PR group
experienced more days without pain attacks compared
with patients in the oxycodone/naloxone PR group.
Effectiveness and Neuropathic Pain-related Symptoms
by Baseline painDETECT Score and Effectiveness in the
Lumbar Radiculopathy Subset
Mean pain intensity scores at each visit are summarized
for the full analysis set by baseline painDETECT score in
Figure S2. In the full analysis set, improvements in pain
intensity from baseline to final evaluation were compa-
rable for patients with painDETECT unclear and
positive ratings at baseline in both the tapentadol PR
group (unclear, n = 33; positive, n = 96) and the oxy-
codone/naloxone PR group (unclear, n = 27; positive,
n = 96). Significant decreases were observed in pain
A B
C
Figure 8. (A) Mean (SD) painDETECT final scores at baseline and final evaluation, (B) change in painDETECT final scores at baseline and
final evaluation (LS mean), and (C) mean (SD) painDETECT individual item scores at baseline and final evaluation (LOCF; full analysis
set).a,b SD, standard deviation; LS, least squares; LOCF, last observation carried forward; PR, prolonged release; FE, final evaluation; SEM,
standard error of the mean; BL, baseline; ANCOVA, analysis of covariance. *P < 0.001 for the change from baseline. †P = 0.002
(superiority; tapentadol PR vs. oxycodone/naloxone PR). ‡P ≤ 0.029 (superiority; tapentadol PR vs. oxycodone/naloxone PR). aExploratory
analyses. bLSmeans and P valueswere obtained fromanANCOVAmodel that included treatment andpooled centers as factors and score
at randomization (baseline) as a covariate. cFE, n = 115. dFE, n = 124. eSD: burning, BL = 1.18, FE = 1.27; tingling/prickling, BL = 0.92,
FE = 1.26; allodynia, BL = 1.35, FE = 1.31; pain attacks, BL = 1.09, FE = 1.51; thermal pain, BL = 1.33, FE = 1.43; numbness, BL = 1.08,
FE = 1.33; evoked/pressure-related pain, BL = 1.18; FE = 1.49. fSD: burning, BL = 1.29, FE = 1.43; tingling/prickling, BL = 1.17, FE = 1.44;
allodynia, BL = 1.36, FE = 1.24; pain attacks, BL = 1.20, FE = 1.64; thermal pain, BL = 1.41, FE = 1.50; numbness, BL = 1.28, FE = 1.49;
evoked/pressure-related pain, BL = 1.45; FE = 1.48.
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intensity scores from baseline to final evaluation (LOCF)
in the tapentadol PR group (LS mean [SEM] change
from baseline to final evaluation: positive, 4.0 [0.29];
unclear, 3.3 [0.54]) and in the oxycodone/naloxone
PR group (positive, 3.0 [0.30]; unclear, 2.1 [0.56];
all P < 0.001). The reduction in pain intensity was
significantly greater with tapentadol PR than with
oxycodone/naloxone PR in the painDETECT positive
subset (LS mean difference [97.5% CI], 1.0 [1.9,
0.1]; P = 0.007 for superiority). The data showed a
clear trend for greater reductions in pain intensity in the
tapentadol PR group than in the oxycodone/naloxone
PR group in the painDETECT unclear subset, yet the
sample size was too small to reach statistical significance
(LS mean difference [97.5% CI], 1.2 [2.9, 0.6];
P = 0.066 for superiority).
For patients who had a diagnosis of lumbar radicul-
opathy at baseline (a subset of the painDETECT positive
subgroup), significant improvements in pain intensity
from baseline to final evaluation were observed with
both tapentadol PR (LS mean [SEM] change from
baseline to final evaluation, 3.5 [0.34]) and oxyco-
done/naloxone PR (2.1 [0.35]; both P < 0.001; Fig-
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Figure 9. (A) Change from baseline to final evaluation in the NPSI subscores, and (B) number of pain attacks during the previous 24
hours as reported on the NPSI at baseline and final evaluation (full analysis set; LOCF).a,b NPSI, Neuropathic Pain Symptom Inventory;
LOCF, last observation carried forward; LS, least-squares; PR, prolonged release; BL, baseline; FE, final evaluation; ANCOVA, analysis of
covariance. *P < 0.001 for the change from baseline. †P ≤ 0.005 (superiority; tapentadol PR vs oxycodone/naloxone PR). ‡P < 0.001
(superiority; tapentadol PR vs oxycodone/naloxone PR). aExploratory analyses. bLS means and P values were obtained from an ANCOVA
model that included treatment and pooled centers as factors and score at randomization (baseline) as a covariate. cPercent difference
between tapentadol PR and oxycodone/naloxone PR, using oxycodone/naloxone PR as the base (denominator), 34.9%. dPercent
difference between tapentadol PR and oxycodone/naloxone PR, using oxycodone/naloxone PR as the base (denominator), 46.5%.
ePercent difference between tapentadol PR and oxycodone/naloxone PR, using oxycodone/naloxone PR as the base (denominator),
36.0%. fPercent difference between tapentadol PR and oxycodone/naloxone PR, using oxycodone/naloxone PR as the base
(denominator), 48.4%. gPercent difference between tapentadol PR and oxycodone/naloxone PR, using oxycodone/naloxone PR as
the base (denominator), 44.1%.
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greater with tapentadol PR than with oxycodone/
naloxone PR (LS mean difference [97.5% CI], 1.3
[2.3, 0.4]; P = 0.001 for superiority).
In the painDETECT positive subset, mean (SD)
baseline total painDETECT scores were 24.5 (4.13) in
the tapentadol PR group and 24.5 (3.22) in the
oxycodone/naloxone PR group; significant decreases
were observed in both treatment groups from baseline to
final evaluation (LS mean [SEM] change from baseline
to final evaluation, 12.4 [0.83] and 9.6 [0.84],
respectively, both P < 0.001; Figure S4A,B). In the
painDETECT unclear subset, mean (SD) baseline total
painDETECT scores in the tapentadol PR and oxyco-
done/naloxone PR groups, respectively, were 16.2
(1.42) and 16.3 (1.41); the mean total painDETECT
score decreased significantly from baseline to final
evaluation in the tapentadol PR group (LS mean
[SEM] change from baseline, 5.6 [1.26]; P < 0.001),
but not in the oxycodone/naloxone PR group (1.7
[1.37]; P = 0.219; Figure S4C,D). Decreases in the total
painDETECT score were significantly greater in the
tapentadol PR group than in the oxycodone/naloxone
PR group for patients with a painDETECT positive
score at baseline (P = 0.012) and for those with a
painDETECT unclear score at baseline (P = 0.038).
Individual item scores on the painDETECT question-
naire at baseline and final evaluation are summarized by
treatment group and painDETECT rating at baseline in
Figure S5. In the painDETECT positive subset, signifi-
cantly greater decreases from baseline to final evaluation
were observed in the tapentadol PR group than in the
oxycodone/naloxone PR group of the painDETECT
positive subset for the following individual item scores:
suffering from a burning sensation in the marked area, a
tingling or prickling sensation in the area of pain, and
cold or heat occasionally painful in the area (thermal
pain; all P < 0.02; Figure S5A). In the painDETECT
unclear subset, the decrease from baseline to final
evaluation was significantly greater in the tapentadol
PR group than in the oxycodone/naloxone PR group for
the individual item score of slight pressure triggers pain
in the area (evoked/pressure-related pain; P < 0.02;
Figure S5B).
The NPSI overall feeling score also improved signif-
icantly from baseline to final evaluation for patients with
baseline painDETECT positive and unclear scores in the
tapentadol PR group (both P < 0.001) and the oxyco-
done/naloxone PR group (both P ≤ 0.013), and
improvements were significantly greater in the tapent-
adol PR group than in the oxycodone/naloxone PR
group for both painDETECT subsets (P ≤ 0.008).
Changes from baseline to final evaluation in NPSI
subscores are summarized by treatment group and
painDETECT rating at baseline in Figure S6.
System Organ Class, n (%)
Preferred Term, n (%)











Gastrointestinal disorders 64 (50.0) 53 (40.8) 66 (51.6) 58 (44.6)
Constipation 33 (25.8) 16 (12.3)* 33 (25.8) 20 (15.4)*,†
Nausea 23 (18.0) 28 (21.5) 23 (18.0) 29 (22.3)
Vomiting 21 (16.4) 9 (6.9)* 21 (16.4) 10 (7.7)*,‡
Dry mouth 7 (5.5) 8 (6.2) 7 (5.5) 9 (6.9)
Nervous system disorders 33 (25.8) 34 (26.2) 35 (27.3) 38 (29.2)
Dizziness 22 (17.2) 22 (16.9) 22 (17.2) 24 (18.5)




32 (25.0) 40 (30.8) 35 (27.3) 40 (30.8)
Fatigue 30 (23.4) 39 (30.0) 31 (24.2) 39 (30.0)
Skin and subcutaneous
tissue disorders
22 (17.2) 14 (10.8) 24 (18.8) 16 (12.3)
Hyperhidrosis 10 (7.8) 7 (5.4) 13 (10.2) 8 (6.2)
Pruritus 11 (8.6) 7 (5.4) 11 (8.6) 8 (6.2)
Infections and infestations 6 (4.7) 4 (3.1) 11 (8.6) 19 (14.6)
Nasopharyngitis 2 (1.6) 2 (1.5) 5 (3.9) 8 (6.2)
TEAE, treatment-emergent adverse event; PR, prolonged release.
*P ≤ 0.045 vs. oxycodone/naloxone PR.
†Percent difference between tapentadol PR and oxycodone/naloxone PR, using oxycodone/naloxone PR as the base
(denominator), 40.3%.
‡Percent difference between tapentadol PR and oxycodone/naloxone PR, using oxycodone/naloxone PR as the base
(denominator), 53.1%.
Table 2. TEAEs Reported for ≥5%
of Patients in Either Treatment
Group During the Titration Period
and the Overall Treatment Period
(Safety Set)
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Tolerability
In the tapentadol PR and oxycodone/naloxone PR
groups of the safety set, respectively, ≥1 TEAE was
reported for 66.2% (86/130) and 75.8% (97/128) of
patients during the titration period and for 76.9%
(100/130) and 83.6% (107/128) of patients during the
overall treatment period. The overall incidence of
gastrointestinal disorders was numerically lower in the
tapentadol PR group than in the oxycodone/naloxone
PR group during both the titration period and the
overall treatment period (Table 2). The incidences of
constipation and vomiting were significantly lower in
the tapentadol PR group than in the oxycodone/nalox-
one PR group during titration and the overall treatment
period (all P ≤ 0.045).
Overall, 21.5% (28/130) of patients in the tapentadol
PR group and 42.2% (54/128) of patients in the
oxycodone/naloxone PR group experienced a TEAE
that led to study discontinuation (P < 0.001 for tapent-
adol PR vs. oxycodone/naloxone PR). For the oxyco-
done/naloxone PR group, this included 35 patients who
dropped into the open-label pickup arm due to TEAEs.
In the tapentadol PR and oxycodone/naloxone PR
groups, respectively, gastrointestinal TEAEs led to study
discontinuation in 14.6% (19/130) and 21.1% (27/128)
of patients, and nervous system TEAEs led to study
discontinuation in 4.6% (6/130) and 17.2% (22/128) of
patients (P = 0.001 for tapentadol PR vs. oxycodone/
naloxone PR).
Effectiveness, Neuropathic Pain-related Symptoms, and
Tolerability in the Pickup Arm
For 50 patients who switched from oxycodone/nalox-
one PR to tapentadol PR in the pickup arm, the mean
(SD) pain intensity score at baseline (randomization) of
the overall study was 7.6 (1.01), and the mean (SD) pain
intensity score at baseline of the pickup arm was 5.8
(1.96). The mean (SD) pain intensity score was lower at
all study visits and at final evaluation (4.5 [2.10]) than at
baseline (randomization) of the overall study or at
pickup baseline. Significant decreases in mean pain
intensity were observed from baseline (randomization)
to final evaluation (mean [SD] change from baseline,
3.1 [2.08]; P < 0.001) and from pickup baseline to
final evaluation (1.3 [2.50]; P < 0.001).
painDETECT scores also decreased over the course of
tapentadol PR treatment in the pickup arm. For patients
in the pickup arm, themean (SD) painDETECT score was
22.1 (5.33) at baseline (randomization) of the overall
study, 17.9 (7.48) at the pickup baseline, and 13.1 (6.94)
at final evaluation. Significant decreases were observed in
the mean painDETECT score from baseline to final
evaluation (mean [SD] change from baseline,9.0 [7.18];
P < 0.001) and from pickup baseline to final evaluation
(4.3 [6.92]; P < 0.001). Mean NPSI overall feeling
score and all subscores also improved significantly from
baseline of the overall study and from pickup baseline for
patients in the pickup arm (all P ≤ 0.001).
Overall, 58.0% (29/50) of patients in the pickup arm
reported ≥1 TEAE. In the subset of patients who entered
the pickup arm, the incidences of the most frequently
reported TEAEs (incidence ≥10%) were numerically
lower during treatment with tapentadol PR in the pickup
arm than during prior treatment with oxycodone/nalox-
one PR, as follows: dizziness (12.0% [6/50] vs. 26.0%
[13/50]), nausea (10.0% [5/50] vs. 24.0% [12/50]),
vomiting (8.0% [4/50] vs. 22.0% [11/50]), fatigue
(4.0% [2/50] vs. 20.0% [10/50]), constipation (2.0%
[1/50] vs. 26.0% [13/50]), and drymouth (0%vs. 12.0%
[6/50]).
DISCUSSION
Rationale for the Trial Design and Methodology
Chronic low back pain often has a neuropathic pain
component.2,37 Results of an epidemiologic survey of
8,000 patients with low back pain indicate that a
neuropathic pain component (assessed using the pain-
DETECT questionnaire) is likely or unclear (ie, could
not be excluded) in 64.7% of patients overall with
chronic low back pain2; for patients with severe chronic
low back pain, this percentage increases to 76.6%.2
However, neuropathic pain, including low back pain
with a neuropathic pain component, is often challenging
to diagnose and manage4,5; the neuropathic pain com-
ponent may be undiagnosed in many patients with low
back pain. Therapeutics that affect ascending pain
pathways or only a target, such as the MOR, may not
fully address the neuropathic component of low back
pain38–40 because of the potential involvement of
descending noradrenergic pain pathways in the modu-
lation of neuropathic pain.41 Furthermore, opioid anal-
gesics may be associated with poor tolerability,7–9 and
combination therapy with an opioid and a co-analgesic
may be associated with a higher incidence of side effects
and related discontinuations than monotherapy.39,42,43
Other options are needed to optimally address low back
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pain because a neuropathic pain component is present in
most cases.
The NRI component of the analgesic activity of
tapentadol contributes to the efficacy of tapentadol for
neuropathic pain, based on preclinical and clinical
experience.14,19,20,44,45 Based on these previous find-
ings14,19,20,44,45 and recent evidence that indicates that
tapentadol restores descending pain inhibition,18
tapentadol PR may have a preferred analgesic activity
profile for the treatment of chronic low back pain for
which a neuropathic pain component cannot be
excluded.
This randomized, multicenter, parallel-arm, active-
controlled, phase 3b/4 study was designed to evaluate
the effectiveness and tolerability of tapentadol PR
compared with oxycodone/naloxone PR in non–
opioid-pretreated patients with severe chronic low back
pain with a neuropathic pain component. This effec-
tiveness study was designed to provide results that are
meaningful in a clinical setting,46 and an open-label
design was considered appropriate. Results from previ-
ous randomized, double-blind, placebo-controlled stud-
ies have established the efficacy and tolerability of
tapentadol PR across a range of chronic pain indica-
tions,21,23–25,47 including low back pain.23 In context,
the results of this current trial are in line with the
favorable outcomes observed in 3 pivotal randomized,
double-blind, placebo-controlled trials in osteoarthritis
and low back pain21,23 and with the results of a
preplanned, pooled analysis of those trials, in which
the superiority of tapentadol PR compared with oxyco-
done [Correction added after initial online publication
on June 12, 2015: the text “oxycodone/naloxone” was
changed to “oxycodone.”] PR was demonstrated for the
primary efficacy endpoints, validated quality of life
parameters, and gastrointestinal tolerability.22,28 After
the efficacy and tolerability of a new medication have
been established in randomized, double-blind, placebo-
controlled studies, the use of open-label, “real-world”
or “pragmatic” effectiveness studies for further charac-
terization and confirmation of the results observed in the
blinded controlled trials is widely accepted by regulatory
agencies and Health Technology Assessment Institu-
tions, including the German Institute for Quality and
Efficiency in Health Care.48 This trial design also
overcomes the limitations associated with double-blind,
randomized, controlled trials, such as the use of highly
selected populations and settings during development
programs that are more dissimilar from clinical practice.
Furthermore, results of “real-world” or “pragmatic”
effectiveness randomized controlled trials (like the
current study) fulfill the criteria for evidence level 1b,
according to evidence-based medicine standards, includ-
ing those of the Cochrane Collaboration.49 Randomized
controlled trials evaluating safety and tolerability gen-
erally have an open-label design, which is in line with
regulatory guidelines. Therefore, the open-label design
of this effectiveness trial was considered appropriate to
evaluate noninferiority and superiority of the effective-
ness and tolerability of tapentadol PR compared with
that of oxycodone/naloxone PR.
This trial also included a pickup arm that allowed
patients with poor effectiveness or tolerability on
oxycodone/naloxone PR to switch to tapentadol PR.
Offering an alternative treatment to patients with
unsatisfactory treatment results related to dose-limiting
AEs or a lack of efficacy under their current analgesic
treatment is common practice for trying to improve
treatment outcomes in a clinical setting, but only if
there is a clear rationale and a chance for improve-
ment. In this respect, tapentadol PR, with its 2
mechanisms of action (MOR agonism and NRI), has
been shown to provide improved efficacy and tolera-
bility compared with oxycodone PR (the active com-
ponent of oxycodone/naloxone PR) for different types
of chronic pain in large, double-blind, randomized,
controlled trials19,22,23,28 and has also been shown to
provide improved tolerability and effectiveness when
rotating from strong opioids to tapentadol PR in a
population of opioid responders with treatment-limit-
ing side effects.20,50 Given the improved tolerability
profile (particularly with regard to gastrointestinal
AEs) of tapentadol PR compared with oxycodone
PR,19,22,23 the inclusion of a tapentadol PR “rescue”
arm seemed justifiable. Tapentadol PR may offer a
central l-opioid–sparing effect, which underlies its
improved gastrointestinal tolerability profile, while the
addition of locally acting naloxone to oxycodone PR
would only affect constipation. Furthermore, tapent-
adol PR may offer a different and improved treatment
profile for neuropathic pain-related symptoms (based
on its NRI activity); therefore, trying tapentadol PR
treatment after a lack of effectiveness with oxycodone/
naloxone PR is likewise justified. On the other hand,
for oxycodone/naloxone PR, tolerability advantages
compared with oxycodone PR have thus far only been
described in opioid-pretreated and opioid-tolerant
populations.11,12 Furthermore, relevant advantages
due to the addition of naloxone were not anticipated
for gastrointestinal symptoms such as nausea and/or
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vomiting because these symptoms are mainly triggered
centrally, where naloxone would not have a relevant
impact. The pickup arm did not appear to have an
influence on the discontinuation rate in the oxycodone/
naloxone PR group (61.5%), which was comparable
to that observed with oxycodone PR (61.7%) in the
pooled analysis of data from 3 large-scale, double-
blind, randomized, placebo- and active-controlled,
phase 3 trials.22 Thus, results of the current trial were
generally consistent with those of earlier, double-blind,
randomized, controlled trials that did not include the
option of a pickup arm.21–23,28
In a comparative clinical trial, the titration regimen
must be fair and adequate in consideration of the trial
setting and objectives, as was the case in the current
study. The titration regimen used in this study allowed
for equianalgesic dose increases, which avoided bias
associated with underdosing one of the 2 compounds if
unequal dose steps were used. There is some variation
in the titration regimens used for patients treated
with oxycodone/naloxone PR; in general, low doses
(eg, 5/2.5 mg bid) are not approved as starting doses,
while increments of 10/5 mg bid (as used in the current
study) are in line with the United States Food and Drug
Administration–approved prescribing information.51
The use of longer titration regimens for oxycodone/
naloxone PR is not uncommon, as demonstrated in a
recent randomized controlled trial of oxycodone/nalox-
one PR that was conducted for regulatory purposes; in
that study, doses were titrated in increments of 10/5 mg
bid once weekly.52 Therefore, the titration schedule used
in the current study, which offered the potential for up-
titration every 3 days, was considered appropriate for
both compounds.
The selected study population, which included only
patients who were not previously taking opioid analge-
sics, differed from that in previous studies of oxycodone/
naloxone PR, which only showed improved tolerability
compared with oxycodone PR in populations who were
currently taking opioid analgesics for their pain.11,12
The population of the current study was expected to be
more susceptible to tolerability issues than an opioid-
experienced population and would thereby provide the
best possible basis for comparison of opioid-induced
side effects.
Effectiveness and Tolerability
In this study, both tapentadol PR and oxycodone/
naloxone PR provided significant reductions in pain
intensity from baseline to final evaluation in non–
opioid-pretreated patients with severe chronic low back
pain with a neuropathic pain component. The primary
effectiveness endpoint of the trial was formally shown
to be positive, demonstrating noninferiority for tapent-
adol PR vs. oxycodone/naloxone PR for the change
from baseline to final evaluation in pain intensity (11-
point NRS-3). For the primary effectiveness endpoint,
the effectiveness of tapentadol PR was also demon-
strated to be superior to that of oxycodone/naloxone
PR, by means of clinical relevance and statistical
significance (confirmatory evidence of superiority).
Points to consider when switching from noninferiority
to superiority in clinical trials were accounted for in
this analysis.36 Overall, tapentadol PR was associated
with 37% more pain reduction than oxycodone/
naloxone PR (with the percent difference between
tapentadol PR and oxycodone/naloxone PR calculated
using oxycodone/naloxone PR as the base [denomina-
tor]) for providing strong pain relief (Figure 4). Results
of the PGIC, which is considered a key outcome in
chronic pain clinical trials,30 support these effectiveness
outcomes.
Both tapentadol PR and oxycodone/naloxone PR
were associated with significant improvements in
neuropathic pain-related symptoms from baseline to
final evaluation, based on changes in the painDETECT
and NPSI questionnaires. Tapentadol PR provides
better control of neuropathic pain-related symptoms
than oxycodone/naloxone PR. Tapentadol PR showed
a significantly greater reduction in neuropathic pain-
related symptoms than oxycodone/naloxone PR, based
on significantly greater improvements from baseline to
final evaluation in the painDETECT final score, and
the NPSI overall feeling score and all subscores.
Furthermore, the percentage of patients experiencing
no pain attacks at final evaluation was higher in the
tapentadol PR group than in the oxycodone/naloxone
PR group.
Tapentadol PR was generally well tolerated and was
associated with significantly less constipation and vom-
iting than oxycodone/naloxone PR during both the
titration period and the overall treatment period.
Tapentadol was associated with approximately 40%
less constipation (with the percent difference between
tapentadol PR and oxycodone/naloxone PR calculated
using oxycodone/naloxone PR as the base [denomina-
tor]) during the overall treatment period (Table 2). As
presented separately, for the co-primary endpoint,
tapentadol PR was shown to be noninferior to oxyco-
Effectiveness of Tapentadol PR vs. Oxycodone/Naloxone PR  595
done/naloxone PR for the change in the PAC-SYM total
score from baseline to final evaluation.29
Effectiveness by Baseline painDETECT Score and in the
Lumbar Radiculopathy Subset
Minor differences were observed in results for the
subsets of patients divided by baseline painDETECT
score (positive or unclear). Similar significant improve-
ments from baseline to final evaluation were observed in
pain intensity scores in the painDETECT positive
and unclear subsets and for patients with a lumbar
radiculopathy diagnosis at baseline; the reduction
in pain intensity was significantly greater with tapent-
adol PR than with oxycodone/naloxone PR in the
painDETECT positive subset and for patients with a
lumbar radiculopathy diagnosis at baseline. Although
the LS mean difference showed an even greater differ-
ence between the tapentadol PR and oxycodone/nalox-
one PR groups in the painDETECT unclear subset than
the painDETECT positive subset; the difference did not
reach statistical significance, considering the small
sample size. In both baseline painDETECT subsets,
tapentadol PR was associated with significantly greater
improvements from baseline to final evaluation in the
total painDETECT score, overall NPSI score, and all
NPSI subscores than oxycodone/naloxone PR.
Effectiveness and Tolerability in the Pickup Arm
Results from the pickup arm showed that patients in
this study who discontinued treatment with oxyco-
done/naloxone PR due to poor effectiveness or
tolerability experienced improvements in pain inten-
sity, neuropathic pain-related symptoms, and tolera-
bility after switching to tapentadol PR treatment in
the pickup arm. Tolerability comparisons are based
on the total incidences of these TEAEs during prior
study treatment with oxycodone/naloxone PR and
during treatment with tapentadol PR in the pickup
arm; it is possible that some of the TEAEs reported
during oxycodone/naloxone PR treatment may have
resolved prior to entering the pickup arm. Therefore,
pretreatment with oxycodone/naloxone PR and the
method of recording AEs should be taken into
account when interpreting these results. Still, these
results support those of a previous phase 3b study
that showed that patients with severe chronic low
back pain who rotated directly from WHO step III
opioids to tapentadol PR experienced statistically
significant improvements in pain intensity and neuro-
pathic pain-related symptoms, despite the fact that
their pain was well controlled at baseline with their
prior analgesic regimen; 62.4% of patients in that
study had at least a possible neuropathic component
(painDETECT unclear or positive score at baseline) to
their low back pain.20
Dosing Ratio and Superiority
Mean doses of tapentadol PR and oxycodone/naloxone
PR in the current study were in line with the 5:1
equianalgesic ratio established for tapentadol PR vs.
oxycodone PR in earlier randomized controlled stud-
ies;21,23 however, tapentadol PR was associated with
superior analgesic effectiveness to that of oxycodone/
naloxone PR. These results also support previous evi-
dence from the pooled analysis of data from 3 random-
ized, double-blind, placebo- and active-controlled, phase
3 studies in patients with moderate to severe chronic
osteoarthritis pain or low back pain; results of that
analysis showed that tapentadol PR (100 to 250 mg bid)
provided noninferior and even superior analgesic efficacy
to that of oxycodone PR (20 to 50 mg bid), with superior
gastrointestinal tolerability at a 5:1 ratio of mean modal
daily doses after dose stabilization.28
CONCLUSIONS
In this study, both tapentadol PR and oxycodone/
naloxone PR provided significant reductions in pain
intensity from baseline to final evaluation in non–
opioid-pretreated patients with severe chronic low
back pain with a neuropathic pain component. The
primary effectiveness endpoint of the study was
formally shown to be positive, demonstrating nonin-
feriority for tapentadol PR vs. oxycodone/naloxone
PR. The effectiveness of tapentadol PR was shown to
be superior to that of oxycodone/naloxone PR by
means of clinical relevance and statistical significance
(confirmatory evidence of superiority). Both study
treatments were associated with significant reductions
in neuropathic pain-related symptoms, and these
improvements were significantly greater with tapent-
adol PR than with oxycodone/naloxone PR. In
general, there were significantly better overall out-
comes for PGIC and CGIC with tapentadol PR vs.
oxycodone/naloxone PR, with a significantly greater
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percentage of patients and investigators, respectively,
reporting ratings of “much improved” or “very much
improved.” Tapentadol PR was generally safe and well
tolerated, with a significantly better gastrointestinal
tolerability profile. Overall, these results show that
tapentadol PR is effective in managing severe chronic
low back pain and is superior to oxycodone/naloxone
PR in providing strong pain relief. Based on these
study results, tapentadol PR may be considered a first-
line option for managing severe chronic low back pain
with a neuropathic pain component.
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